Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001069163 | SCV001234312 | likely benign | Noonan syndrome 9 | 2024-01-27 | criteria provided, single submitter | clinical testing | |
St. |
RCV001069163 | SCV003928093 | uncertain significance | Noonan syndrome 9 | 2023-04-03 | criteria provided, single submitter | clinical testing | The SOS2 c.3289T>C (p.Ser1097Pro) missense change has a maximum subpopulation frequency of 0.022% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL is inconclusive about a pathogenic or benign effect of this variant on protein function, and to our knowledge functional studies have not been performed. To our knowledge, this variant has not been reported in individuals with Noonan syndrome. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |
Ambry Genetics | RCV004030701 | SCV004957704 | uncertain significance | Cardiovascular phenotype | 2022-05-05 | criteria provided, single submitter | clinical testing | The c.3289T>C (p.S1097P) alteration is located in exon 20 (coding exon 20) of the SOS2 gene. This alteration results from a T to C substitution at nucleotide position 3289, causing the serine (S) at amino acid position 1097 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004689983 | SCV005185497 | likely benign | not specified | 2024-05-06 | criteria provided, single submitter | clinical testing |